Vis børsmeldingen
GOTHENBURG, 29 November 2024
On 30 August 2024, it was announced that the Company had adopted a
cross-border merger plan with Carasent ASA, with the Company as the acquiring
entity, in order to effect the relisting of Carasent ASA’s shares on Nasdaq
Stockholm (the “Relisting”). On 8 November 2024, it was announced that Nasdaq
Stockholm had assessed that Nasdaq Stockholm’s listing requirements have been
fulfilled and that Nasdaq Stockholm will approve an application for admission
to trading of the Company’s shares, subject to the fulfilment of certain
customary conditions, including the approval and registration of a prospectus
by the Swedish Financial Supervisory Authority.
The Swedish language prospectus in relation to the Relisting has today been
approved by the Swedish Financial Supervisory Authority and is available on
the Company’s website, www.carasent.com (http://www.carasent.com/). The
prospectus will also be available on the Swedish Financial Supervisory
Authority’s website, www.fi.se (http://www.fi.se/).
The cross-border merger is expected to be completed on 4 December 2024, upon
which shareholders will have their shares in Carasent ASA exchanged
one-for-one with shares in the Company. The last day of trading on Oslo Børs
is expected to be 4 December 2024 and the first day of trading on Nasdaq
Stockholm is expected to be 9 December 2024. The dates can be changed and if
so, this will be separately announced.
Carnegie Investment Bank AB is acting as sole financial advisor to Carasent,
Advokatfirman Vinge is acting as legal advisor to Carasent on Swedish legal
matters and Advokatfirmaet BAHR are acting as legal advisor to Carasent on
Norwegian legal matters.
For further information, please contact
Daniel Öhman, CEO
Tel: +46 70-855 37 07, e-mail: daniel.ohman@carasent.com
Svein Martin Bjørnstad, CFO
Tel: +47 979 69 493, e-mail: svein.martin.bjornstad@carasent.com
The information was submitted for publication, through the agency of the
contact persons set out above, on 29 November 2024 at 14.20 CET.
Carasent AB (publ) (Nasdaq Stockholm: CARA) delivers cloud based EHR
solutions, with Webdoc as the leading platform, and a broad ecosystem of
platform services, including solutions for patient communication and business
intelligence. Since 2020 six acquisitions have been completed, adding new
products to the portfolio, including the EHR solutions Metodika, Ad Curis and
Ad Opus, the business intelligence software Medrave and occupational care
platform HPI. The ecosystem of solutions makes Carasent a one-stop shop for
clinics and can cover all needs. Carasent believes in innovation that offers a
new kind of accessibility and availability for patients and practices. The
growing product portfolio comprises market-leading software solutions
developed closely with customers and the respective target market.
IMPORTANT INFORMATION
The publication, release or distribution of this press release may be
restricted in certain jurisdictions. Recipients of this press release in the
jurisdictions in which this press release has been published, released or
distributed should inform themselves about and observe such restrictions. This
press release does not constitute an offer, or a solicitation of any offer, to
buy or subscribe for any securities in Carasent in any jurisdiction.
This press release does not identify or attempt to identify any risks (direct
or indirect) that may be associated with an investment in securities of
Carasent. The information contained in this press release is published for
background purposes only and does not purport to be complete.
This press release does not constitute an offer or invitation to purchase or
subscribe for securities in the United States. The securities referred to
herein may not be sold in the United States absent registration or an
applicable exemption from registration under the U.S. Securities Act of 1933,
as amended. The information contained in this press release may not be
announced, published, copied, reproduced or distributed, directly or
indirectly, in whole or in part, in or into the United States, Australia,
Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland,
Singapore, South Africa, South Korea or any other jurisdiction where such
announcement, publication or distribution of this information would be
contrary to applicable laws and regulations.
This press release is not a prospectus as defined in Regulation (EU) 2017/1129
(the “Prospectus Regulation”) and has not been approved by any regulatory
authority in any jurisdiction. Carasent has not authorized any offer of
securities to the public in any member state of the European Economic Area
(“EEA”).
This press release contains certain forward-looking statements that reflect
the Company’s current views with respect to future events and financial and
operational performance. Words such as “intends”, “expects”, “anticipates”,
“may”, “plans”, “believes”, “estimates” and other expressions that are
indicative or predictive of future developments or trends, and that are not
based on historical facts, constitute forward-looking statements. By its
nature, forward-looking information involves known and unknown risks and
uncertainties because it is dependent on future events and circumstances.
Forward-looking statements are not guarantees of future performance or
development and actual results may differ materially from those expressed in
the forward-looking statements.
Kilde
